Sino Biopharmaceutica Ownership
| SBMFF Stock | USD 0.37 0.04 9.76% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Sino |
Sino Pink Sheet Ownership Analysis
About 48.0% of the company outstanding shares are owned by corporate insiders. The book value of Sino Biopharmaceutica was at this time reported as 1.64. The company has Price/Earnings To Growth (PEG) ratio of 0.53. Sino Biopharmaceutical last dividend was issued on the 6th of September 2022. The entity had 3:2 split on the 4th of June 2018. Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the Peoples Republic of China. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong. Sino Biopharmaceutic is traded on OTC Exchange in the United States.The quote for Sino Biopharmaceutical Limited is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Sino Biopharmaceutical Limited contact Eric Tse at 852 2802 9886 or learn more at https://www.sinobiopharm.com.Currently Active Assets on Macroaxis
| EBR | Centrais Electricas Brasileiras | |
| HE | Hawaiian Electric Industries | |
| VFC | VF Corporation | |
| BVHMF | Vistry Group PLC | |
| S | SentinelOne |
Other Information on Investing in Sino Pink Sheet
Sino Biopharmaceutica financial ratios help investors to determine whether Sino Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sino with respect to the benefits of owning Sino Biopharmaceutica security.